News | July 16, 2022
Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Site Enhances New Modality CRDMO Platform Capacity for Customers
Younger Indians have a 10 times higher rate of heart attack
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
Subscribe To Our Newsletter & Stay Updated
